Eckert & Ziegler SE (ETR:EUZ)
Germany · Delayed Price · Currency is EUR | Market Cap | 907.36M -7.3% |
| Revenue (ttm) | 316.81M +4.1% |
| Net Income | 54.35M +36.7% |
| EPS | 0.87 +38.7% |
| Shares Out | 62.58M |
| PE Ratio | 16.70 |
| Forward PE | 16.85 |
| Dividend | 0.22 (1.52%) |
| Ex-Dividend Date | Jun 25, 2026 |
| Volume | 144,876 |
| Open | 13.81 |
| Previous Close | 13.93 |
| Day's Range | 13.80 - 14.57 |
| 52-Week Range | 11.91 - 17.47 |
| Beta | 1.33 |
| Analysts | Strong Buy |
| Price Target | 21.60 (+48.97%) |
| Earnings Date | Nov 12, 2026 |
About Eckert & Ziegler SE
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceu... [Read more]
Financial Performance
In 2025, Eckert & Ziegler SE's revenue was 311.96 million, an increase of 5.45% compared to the previous year's 295.85 million. Earnings were 48.76 million, an increase of 46.54%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for EUZ stock is "Strong Buy." The 12-month stock price target is €21.60, which is an increase of 48.97% from the latest price.
News
Pentixapharm Extends €18.5 Mln Convertible Bond To 2030, Raises Interest Rate
(RTTNews) - Pentixapharm Holding AG (PTP.DE) said it entered into an agreement with Eckert & Ziegler SE (EUZ.DE), its sole bondholder, to extend its €18.5 million convertible bond to December 31, 2030...
Eckert & Ziegler SE Quarterly report: Q3 2026
Eckert & Ziegler SE has published its Q3 2026 quarterly earnings report on November 12, 2026.
Eckert & Ziegler SE Slides: Q3 2026
Eckert & Ziegler SE has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 12, 2026.
EQS-Adhoc: Pentixapharm Holding AG extends drawdown period and term of its convertible bond with Eckert & Ziegler SE to 2030 with adjusted terms
EQS-Ad-hoc: Pentixapharm Holding AG / Key word(s): Other Pentixapharm Holding AG extends drawdown period and term of its convertible bond with Eckert & Ziegler SE to 2030 with adjusted terms 12-Nov-20...
Eckert & Ziegler: Q3 Adjusted EBIT Soars 25%; 2026 Forecast Confirmed
Eckert & Ziegler posted strong Q3 earnings growth and reaffirmed its 2026 outlook, backed by Medical segment momentum, robust demand and expected Q4 license revenue.
Eckert & Ziegler, TerThera Sign Tb-161 Supply Deal For Cancer Therapies In Brazil
(RTTNews) - Eckert & Ziegler SE (EUZ.F) and TerThera BV have signed a strategic supply agreement for Terbium-161 (Tb-161), a radioisotope being investigated for targeted cancer therapies, to support r...
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
Eckert & Ziegler SE Slides: Investor presentation
Eckert & Ziegler SE has posted slides in relation to its latest quarterly earnings report, which was published on September 22, 2026.
Q2 review: underlying business solid, valuation attractive: Despite a slight consensus miss with Q2, ...
Eckert & Ziegler reported H1 results: adj. EBIT grew 10% yoy ex license, with the margin up 1.2pp to 22.3%, while reported adj. EBIT fell 6% yoy to € 33.3m against a base carrying € 5m of license i...
Eckert & Ziegler SE Earnings Call Transcript: Q2 2026
First half 2026 saw stable revenues and 5% net income growth, with strong performance in medical and radiopharmaceuticals. Full-year guidance is maintained, expecting a stronger H2 driven by license payments and improved product mix. Cash remains strong and the company is nearly debt-free.
Eckert & Ziegler SE Quarterly report: Q2 2026
Eckert & Ziegler SE has published its Q2 2026 quarterly earnings report on August 13, 2026.
Eckert & Ziegler SE Slides: Q2 2026
Eckert & Ziegler SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
Eckert & Ziegler SE Slides: FY 2026
Eckert & Ziegler SE has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 26, 2026.
Original-Research: Eckert & Ziegler SE (von NuWays AG): BUY
Original-Research: Eckert & Ziegler SE - from NuWays AG 13.05.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible ...
Eckert & Ziegler SE Earnings Call Transcript: Q1 2026
Q1 2026 saw 7% sales growth and strong medical segment performance, offsetting a slow start in the IP segment. Full-year guidance is reaffirmed, with robust cash reserves and a focus on organic growth and targeted M&A. Competitive and market conditions remain stable.
Eckert & Ziegler SE Quarterly report: Q1 2026
Eckert & Ziegler SE has published its Q1 2026 quarterly earnings report on May 12, 2026.
Eckert & Ziegler SE Slides: Q1 2026
Eckert & Ziegler SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
Eckert & Ziegler SE Earnings Call Transcript: Q4 2025
Sales exceeded €300 million in 2025, driven by medical segment growth and global expansion, with EBIT margin at 25% and strong cash flow. 2026 guidance targets €320 million sales and €80 million EBIT adjusted, with continued CapEx and cautious outlook on license income and FX impacts.
Eckert & Ziegler SE Annual report: Q4 2025
Eckert & Ziegler SE has published its Q4 2025 annual report on March 26, 2026.
Eckert & Ziegler SE Slides: Q4 2025
Eckert & Ziegler SE has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 26, 2026.
Eckert & Ziegler SE Annual report: Q4 2025
Eckert & Ziegler SE has published its Q4 2025 annual report on March 26, 2026.
EQS-DD: Eckert & Ziegler SE: Dr. Gunnar Mann, Allocation of 12,545 shares as part of executive board remuneration (own shares of the issuer). This is a share-based remuneration with an automatic ...
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24.03.2026 / 10:17 CET/CEST The issuer is solely responsi...